{"id":941139,"date":"2026-03-02T13:45:37","date_gmt":"2026-03-02T18:45:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/"},"modified":"2026-03-02T13:45:37","modified_gmt":"2026-03-02T18:45:37","slug":"nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/","title":{"rendered":"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline"},"content":{"rendered":"
\n

PHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC<\/u><\/a> announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)<\/strong> (\u201cUltragenyx\u201d or the \u201cCompany\u201d) on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025<\/strong> (the \u201cClass Period\u201d).<\/p>\n

\n
\n Investor Deadline:<\/em>
\n <\/strong>
\n Investors who purchased Ultragenyx securities during the Class Period may, no later than<\/em>
\n
\n \u00a0April 6, 2026<\/em>
\n <\/strong>
\n , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, <\/em>
\n
\n
\n
\n CLICK HERE<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n .<\/em>\n <\/p>\n

Ultragenyx is a Novato, Calif.-based biopharmaceutical company engaged in the acquisition and development of novel products to treat rare diseases.<\/p>\n

The complaint alleges that defendants misrepresented the results of the ORBIT and COSMIC Phase 3 programs testing the efficacy of setrusumab as a treatment of Osteogenesis Imperfecta.<\/p>\n

According to the lawsuit, investors learned the truth on December 29, 2025, when Ultragenyx disclosed that neither study had met its primary endpoint. This alleged reversal caused the Company\u2019s shares to lose more than 42%<\/em><\/strong> of their value in a single trading day<\/em><\/strong>.<\/p>\n

\n
\n If you are a Ultragenyx investor and would like to learn more about this action, <\/em>
\n <\/strong>
\n
\n
\n
\n CLICK HERE<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or please contact Berger Montague: Andrew Abramowitz at <\/em>
\n <\/strong>
\n
\n
\n
\n aabramowitz@bergermontague.com<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or (215) 875-3015, or Caitlin Adorni at <\/em>
\n <\/strong>
\n
\n
\n
\n cadorni@bergermontague.com<\/u>
\n <\/em>
\n <\/strong>
\n <\/a>
\n
\n or (267)764-4865.<\/em>
\n <\/strong>\n <\/p>\n

\n About Berger Montague<\/strong>
\n
Berger Montague is one of the nation\u2019s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.<\/p>\n

\n For more information or to discuss your rights, please contact:<\/strong>\n <\/p>\n

Andrew Abramowitz
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com<\/a>\u00a0<\/p>\n

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (\u201cUltragenyx\u201d or the \u201cCompany\u201d) on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than \u00a0April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Ultragenyx is a Novato, Calif.-based biopharmaceutical company engaged in the acquisition and development of novel products to treat rare diseases. The complaint alleges that defendants … <\/p>\n

Continue reading “NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (\u201cUltragenyx\u201d or the \u201cCompany\u201d) on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than \u00a0April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Ultragenyx is a Novato, Calif.-based biopharmaceutical company engaged in the acquisition and development of novel products to treat rare diseases. The complaint alleges that defendants … Continue reading "NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T18:45:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline\",\"datePublished\":\"2026-03-02T18:45:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/\"},\"wordCount\":375,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/\",\"name\":\"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=\",\"datePublished\":\"2026-03-02T18:45:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/","og_locale":"en_US","og_type":"article","og_title":"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline - Market Newsdesk","og_description":"PHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) — National plaintiffs\u2019 law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) (\u201cUltragenyx\u201d or the \u201cCompany\u201d) on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through December 26, 2025 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than \u00a0April 6, 2026 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Ultragenyx is a Novato, Calif.-based biopharmaceutical company engaged in the acquisition and development of novel products to treat rare diseases. The complaint alleges that defendants … Continue reading \"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-02T18:45:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline","datePublished":"2026-03-02T18:45:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/"},"wordCount":375,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/","name":"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=","datePublished":"2026-03-02T18:45:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2MzQxNiM3NDYwODcyIzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasdaq-rare-investor-alert-berger-montague-advises-ultragenyx-pharmaceutical-inc-nasdaq-rare-investors-of-an-april-6-2026-deadline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}